LEDGIN-Mediated HIV Integrase Retargeting for Functional Cure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies cannot cure HIV infection due to the presence of a reservoir of latently infected cells, allowing the virus to persist and rebound upon therapy cessation.
Innovation Solution
Compounds that inhibit the binding of retroviral integrase (IN) to LEDGF/p75 (LEDGINs) are administered to reduce integrated proviruses and induce a transcriptionally silent state in the viral reservoir, preventing reactivation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiretroviral therapies are used to suppress HIV replication, then viral replication is controlled, but the viral reservoir cannot be eliminated and rebounds upon therapy cessation
Solution Approach 1:
The patent applies preliminary action by using LEDGINs during the integration phase to modify the integration pattern of proviruses before the latent reservoir is fully established. By interfering with LEDGF/p75-integrase interaction early in the viral life cycle, the treatment directs integration away from transcriptionally active regions, creating a transcriptionally silent reservoir that cannot be reactivated later, thus preventing the need for lifelong treatment.
Solution Approach 2:
The patent employs parameter changes by modifying the integration site selection parameter through LEDGINs. By changing the binding affinity between integrase and LEDGF/p75, the treatment alters where proviruses integrate into the host genome, directing them to transcriptionally inactive regions. This parameter change in integration site selection transforms the reservoir from potentially reactivatable to permanently silent.
2Reliability
If LEDGINs are used to interfere with LEDGF/p75-IN binding, then integrated proviruses are reduced and transcriptionally silent state is induced, but the mechanism differs from conventional antiretroviral approaches
Solution Approach 1:
The patent uses LEDGF/p75 as an intermediary target rather than directly targeting the virus or standard viral enzymes. LEDGINs interfere with the host factor LEDGF/p75 that normally mediates integrase function. By targeting this intermediary host-virus interaction complex rather than the virus directly, the treatment achieves functional cure through a novel mechanism that reduces integrated proviruses and induces transcriptional silence.
3Stability of the object's composition
If the viral reservoir is allowed to establish normally, then HIV persistence is enabled, but retargeting integration can create a transcriptionally silent reservoir resistant to reactivation
Solution Approach 1:
The patent applies local quality by creating spatial heterogeneity in the viral reservoir's transcriptional state through retargeted integration. LEDGINs cause proviruses to integrate specifically into transcriptionally inactive genomic regions (such as heterochromatin or gene deserts) rather than uniformly throughout the genome. This localized integration into specific genomic compartments creates a reservoir that is stable but transcriptionally silent, preventing reactivation while maintaining reservoir integrity.
Data Source
AI summary
The application relates to methods of curing retroviral infections, i.e. ensuring remission of retroviral infections, more particularly HIV infections, by administering a compound which is capable of binding to the LEDGF/p75 binding pocket of HIV-integrase and inhibiting LEDGF/p75-IN protein-protein interaction. The application further relates to the use of LEDGINs in retroviral gene therapy.